



**MATERIAL SAFETY DATA SHEET**

Date Printed: FEB 2009

**METRONIDAZOLE FOR INJECTION, USP**

**SECTION 1. PRODUCT AND COMPANY INFORMATION**

Product Name: Metronidazole for injection, USP  
Supplier: West-Ward Pharmaceuticals  
401 Industrial Way West  
Eatontown, NJ 07724  
Phone (732 542 1191)  
Fax (732 720 6220)  
  
Technical Phone: (800 631 2174)

**SECTION 2. COMPOSITION/INFORMATION ON INGREDIENTS**

CAS No.	Description	% in final Product
443-48-1	Metronidazole	<1.0
7647-14-5	Sodium Chloride	<1.0
7558-79-4	Disodium Hydrogen Phosphate Anhydrous	<0.1
5949-29-1	Citric Acid Monohydrate	<0.1
7732-18-5	Water for Injection	>98.0

Category: Anti-infective

**SECTION 3. HAZARDS IDENTIFICATION, EMERGENCY OVERVIEW**

**SUSPECT CANCER HAZARD.**  
MAY CAUSE CANCER. May cause allergic reactions.

Uses In clinical use, this material is used to treat bacterial and protozoal infections. Possible target organs include the nervous system, reproductive system, liver, lungs, and gastrointestinal system.

Occupational Exposure Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.



General Effects of Exposure	Acute Effects of Exposure: Gastrointestinal effects (may include nausea/vomiting, abdominal pain, diarrhea, dry mouth, colic). Nervous System effects (may include ataxia, tremor, disturbance of speech, lethargy, headache, dizziness, blurred vision). Hypersensitivity (may include drug fever, rash, itching, anaphylaxis). Seizures. Peripherical neuropathies (may include numbness and paralysis). Neutropenia (decreased number of neutrophils). Chronic Effects of Exposure: No data is available on the product itself.
Signs and Symptoms	No signs or symptoms from occupational exposure are known. Clinical data suggest the following: seizures, numbness, tingling in the extremities, headaches, anorexia, vomiting, diarrhea, constipation, furry tongue, thrombocytopenia, palpitation, dizziness, ataxia, rash, painful urination.
Medical Conditions Aggravated by Exposure	Data suggest any preexisting ailments in the following organs: nervous system, hematopoietic system, liver, gastrointestinal system. Concurrent intake
Chemical List as Carcinogen:	
	NTP: Classified 2 IARC: Group 2B OSHA: No

---

#### SECTION 4. FIRST AID MEASURES

---

Eyes:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.



**SECTION 5. FIRE AND EXPLOSION DATA**

**Fire and explosion Data**

Closed Cup Flash Point: N/A  
 Open Cup Flash Point N/A  
 Fire Point: N/A  
 Autoignition: N/A  
 Lower Explosion Limit: N/A  
 General Hazard: None out of the ordinary

Fire Fighting Instructions: Water spray, dry chemical, carbon dioxide or foam as appropriate.  
 Fire Fighting Equipment: Wear self-containing breathing apparatus and protective clothing.  
 Hazardous Combustion Products: None Known.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Clean Up: Wear recommended personal protective equipment. Use appropriate absorbent material to clean affected area. Wipe area with soap and water. Dispose of materials according to the applicable federal, state and/ or local regulations.

**SECTION 7. HANDLING AND STORAGE**

General Handling: When handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mist, and/ or vapors associated with product.  
 Storage Conditions: Store at controlled room temperature 15° - 30°C (59° - 86°F). Protect from light, freezing and excessive heat. [see USP Controlled Room Temperature].

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

Engineering Controls: General room ventilation is usually satisfactory. Use Local exhaust ventilation if necessary.

**Personal Protective Equipment**

Eye protection: Safety glasses or goggles recommended should there be a splash potential.  
 Hand protection: Latex rubber gloves recommended.  
 Respiratory Protection: With satisfactory ventilation, respirators are not required.  
 Skin Protection: Disposable garments if direct skin contact is anticipated.

**Exposure Limits:**

Compound	Issuer	Type	OEL
Metronidazole	OSHA	PEL	NE
	ACGIH	TLV	NE
	...	EEL	NE



# WEST-WARD

PHARMACEUTICALS

---

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

---

Physical Form/ Appearance:	Clear liquid.
Boiling Point/ Boiling Range:	Approximate to Water
Melting Point/ Melting Range:	N/A
Freezing Point:	Approximate to Water
Vapor Pressure:	N/A
Relative Vapor Density:	N/A
Percent Volatiles:	N/A
pH:	4.5 - 7.0

---

## SECTION 10. STABILITY AND REACTIVITY DATA.

---

Stability:	Stable
Conditions to Avoid:	Oxidizing agents.
Hazardous Decomposition:	Toxic fumes of nitrogen oxides.
Hazardous Polymerization:	Will not occur

---

## SECTION 11. TOXICOLOGICAL INFORMATION

---

### Acute Toxicity:

Compound	Type	Route	Species	Dosage
Metronidazole	LD50	Oral	Rat	> 3 g/kg
	LD50	Oral	Mouse	= 3800 mg/kg
	LD50	SC	Mouse	> 3640 mg/kg

### Other: CARCINOGENICITY:

Maybe carcinogenic based on animal data.

### MUTAGENICITY:

Maybe mutagenic.

### REPRODUCTIVE TOXICITY:

No impairment to fertility based on animal data. Maybe fetotoxic based on animal data

---

## SECTION 12. ECOLOGICAL INFORMATION

---

Information is currently not available on the environmental impact of Ceftriaxone. Handle in a manner to prevent spills or releases to the environment.

---

## SECTION 13. DISPOSAL CONSIDERATIONS

---

Dispose of by incineration at an approved /permitted incinerator. Review local, state, and federal regulations for your regulatory area.



---

SECTION 14. TRANSPORT INFORMATION

---

**UN/NA Number:** N/A

**US DOT Hazard Class:** N/A

**Proper Shipping Name:** N/A

**Shipping Label:** N/A

---

SECTION 15. REGULATORY INFORMATION

**U.S. Regulatory Information** : not regulated.

**PROP 65(Calif.)** : Metronidazole is identified in the state of California to cause reproductive toxicity.

---

SECTION 16. OTHER INFORMATION

---

This document has been generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. We do not assume any responsibility and expressly disclaim any liability for any loss, damage, or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.